Acadia Pharmaceuticals (ACAD) Receivables - Other (2013 - 2026)

Acadia Pharmaceuticals' Receivables - Other history runs 14 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 63.52% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (up 63.52% YoY), while the FY2025 annual figure was $26.8 million, up 349.53% from the prior year.
• Receivables - Other was $13.0 million for Q1 2026 at Acadia Pharmaceuticals, down from $26.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $26.8 million in Q4 2025 to a low of $403000.0 in Q3 2022.
• Historically, Receivables - Other has averaged $7.6 million across 5 years, with a median of $5.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other slumped 58.54% in 2022, then surged 602.54% in 2024.
• A 5-year view of Receivables - Other shows it stood at $885000.0 in 2022, then surged by 361.36% to $4.1 million in 2023, then surged by 45.87% to $6.0 million in 2024, then jumped by 349.53% to $26.8 million in 2025, then tumbled by 51.32% to $13.0 million in 2026.
• The last three Receivables - Other figures came in at $13.0 million (Q1 2026), $26.8 million (Q4 2025), and $23.6 million (Q3 2025), per Business Quant data.